Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.51 |
| ▸ | CMA1 | P23946 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5459105 | 0.92 | TAAR1 (0.56) | TAAR1ALDH1A1HSD17B10CYP3A4SLC6A4 | |
| SCHEMBL109195 | 0.86 | TAAR1 (0.64) | TAAR1ALDH1A1CYP3A4SLC6A4CYP1A2 | |
| SCHEMBL108109 | 0.84 | TAAR1 (0.62) | TAAR1ALDH1A1CYP3A4SLC6A4CYP1A2 | |
| SCHEMBL4165040 | 0.82 | KDM4E (0.52) | TAAR1ALDH1A1HSD17B10CYP3A4SLC6A4 | |
| SCHEMBL28393946 | 0.77 | ALDH1A1 (0.58) | TAAR1ALDH1A1HSD17B10CYP3A4SLC6A4 | |
| SCHEMBL6968498 | 0.77 | ALDH1A1 (0.48) | TAAR1ALDH1A1HSD17B10CYP3A4SLC6A4 | |
| SCHEMBL108087 | 0.77 | TAAR1 (0.77) | TAAR1ALDH1A1CYP3A4SLC6A4CYP1A2 | |
| SCHEMBL1422874 | 0.77 | ALDH1A1 (0.58) | TAAR1ALDH1A1CYP3A4SLC6A4CYP1A2 | |
| SCHEMBL7741575 | 0.77 | TAAR1 (0.55) | TAAR1CYP3A4SLC6A4CYP1A2MAPT | |
| SCHEMBL28150474 | 0.76 | ALDH1A1 (0.47) | TAAR1ALDH1A1HSD17B10CYP3A4SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051253-B2 | Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's | PROTEOTECH INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-9051253-B2 | Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's | PROTEOTECH INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-8895554-B2 | Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes, and Parkinson's disease | PROTEOTECH INC (US) | 2014-11-25 | — | — | US | disclosed |
| US-8895554-B2 | Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes, and Parkinson's disease | PROTEOTECH INC (US) | 2014-11-25 | — | — | US | disclosed |
| US-8754133-B2 | Compounds, compositions and methods for the treatment of inflammatory diseases | PROTEOTECH, INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754133-B2 | Compounds, compositions and methods for the treatment of inflammatory diseases | PROTEOTECH, INC. (US) | 2014-06-17 | — | — | US | disclosed |
| EP-2527315-B1 | Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes and Parkinson's disease | PROTEOTECH INC (US) | 2014-03-19 | — | — | EP | disclosed |
| US-20140038980-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES SUCH AS ALZHEIMER'S DISEASE, TYPE 2 DIABETES, AND PARKINSON'S DISEASE | PROTAMED, INC. | 2014-02-06 | — | — | US | disclosed |
| US-20140038980-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES SUCH AS ALZHEIMER'S DISEASE, TYPE 2 DIABETES, AND PARKINSON'S DISEASE | PROTAMED, INC. | 2014-02-06 | — | — | US | disclosed |
| US-8586585-B2 | Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes and Parkinson's disease | PROTEOTECH, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20090069432-A1 | Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; Alzheimer's disease; diabetes; A beta amyloidosis | PROTEOTECH INC. | 2009-03-12 | — | — | US | disclosed |
| WO-2009017848-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES SUCH AS SYSTEMIC AA AMYLOIDOSIS | PROTEO TECH INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2008154083-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES | PROTEO TECH INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008097692-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES | PROTEOTECH INC. (US) | 2008-08-14 | — | — | WO | disclosed |
| US-20070276034-A1 | Compounds, compositions and methods for the treatment of synucleinopathies | PROTEOTECH, INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070276034-A1 | Compounds, compositions and methods for the treatment of synucleinopathies | PROTEOTECH, INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070225362-A1 | Compounds, compositions and methods for the treatment of amyloid diseases such as systemic AA amyloidosis | PROTAMED, INC. | 2007-09-27 | — | — | US | disclosed |
| US-20070225362-A1 | Compounds, compositions and methods for the treatment of amyloid diseases such as systemic AA amyloidosis | PROTAMED, INC. | 2007-09-27 | — | — | US | disclosed |
| US-20070208087-A1 | Compounds, compositions and methods for the treatment of inflammatory diseases | PROTEOTECH INC. | 2007-09-06 | — | — | US | disclosed |
| US-20070208087-A1 | Compounds, compositions and methods for the treatment of inflammatory diseases | PROTEOTECH INC. | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208087-A1 | Compounds, compositions and methods for the treatment of inflammatory diseases | NR1H2, NR1H3, NR1H4 | TAAR1 438/4885ALDH1A1 1308/4885HSD17B10 167/4885 |
| US-20070225362-A1 | Compounds, compositions and methods for the treatment of amyloid diseases such as systemic AA amyloidosis | IAPP, SNCA, APP | TAAR1 1303/4885ALDH1A1 1886/4885HSD17B10 1021/4885 |
| US-20070276034-A1 | Compounds, compositions and methods for the treatment of synucleinopathies | SNCA, PARK7, COMT | TAAR1 2937/4885ALDH1A1 2540/4885HSD17B10 599/4885 |
| US-20140038980-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES SUCH AS ALZHEIMER'S DISEASE, TYPE 2 DIABETES, AND PARKINSON'S DISEASE | IAPP, SNCA, APP | TAAR1 3130/4885ALDH1A1 2767/4885HSD17B10 1480/4885 |
| US-20090069432-A1 | Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; Alzheimer's disease; diabetes; A beta amyloidosis | IAPP, APP, SNCA | TAAR1 2362/4885ALDH1A1 2505/4885HSD17B10 1206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.